The oligonucleotide API business has become a major business of ST Pharm. The company has signed many deals over the past three years and the expansion and expectations for contract extensions have also greatly contributed to improving the company’s performance.

Experts expect the oligonucleotide API business to stay as a cash cow for ST Pharm for a decade to come, with the global surge in demand for oligonucleotide API and the fact that most contracts signed by ST Pharm are long-term contracts.

On the 27th, ST Pharm publicly announced that its oligonucleotide API supply contract with a biotech firm A in the U.S. has been expanded. In November 2019, ST Pharm had signed a contract with t